SUPPLEMENT

Q4 2025 — Financial disclosures

Q4 2025PDF · 10 pages1.2 MB
Merck & Co., Inc.,
Rahway, N.J., USA
Financial Highlights Package
Fourth Quarter 2025
Table of Contents
Table 1: GAAP P&L....................................................................................1
Table 1a: GAAP P&L – Current Year and Prior Year by Quarter.................2
Table 2a: GAAP to Non-GAAP Reconciliation 4Q25 and Dec YTD 25........3
Table 2b: GAAP to Non-GAAP Reconciliation 4Q24 and Dec YTD 24........4
Table 3: Sales - Current Year and Prior Year by Quarter..........................5
Table 3a: Sales – U.S. / International 4Q25.................................................6
Table 3b: Sales – U.S. / International Dec YTD 25......................................7
Table 3c: Sales – Pharmaceutical Geographic Split....................................8
Table 4: Other (Income) Expense .............................................................9

-- 1 of 10 --

Sales 	16,400	$ 	15,624	$ 	5% 	65,011	$ 	64,168	$ 	1%
Costs, Expenses and Other
Cost of sales 	5,551 	3,828 	45% 	16,382 	15,193 	8%
Selling, general and administrative 	2,898 	2,864 	1% 	10,733 	10,816 	-1%
Research and development 	3,886 	4,585 	-15% 	15,789 	17,938 	-12%
Restructuring costs 	213 	51 	* 	889 	309 	*
Other (income) expense, net 	432 	126 	* 	151 	(24) 	*
Income Before Taxes 	3,420 	4,170 	-18% 	21,067 	19,936 	6%
Income Tax Provision 	458 	425 	2,804 	2,803
Net Income 	2,962 	3,745 	-21% 	18,263 	17,133 	7%
Less: Net (Loss) Income Attributable to Noncontrolling Interests 	(1) 	2 	9 	16
Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 	2,963	$ 	3,743	$ 	-21% 	18,254	$ 	17,117	$ 	7%
Earnings per Common Share Assuming Dilution 	1.19	$ 	1.48	$ 	-20% 	7.28	$ 	6.74	$ 	8%
Average Shares Outstanding Assuming Dilution 	2,488 	2,537 	2,507 	2,541
Tax Rate 	13.4% 	10.2% 	13.3% 	14.1%
* 100% or greater
GAAP
% Change
4Q25 	4Q24
GAAP
% Change	Full Year
2025
Full Year
2024
MERCK & CO., INC., RAHWAY, N.J., USA
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1
1

-- 2 of 10 --

Sales 	15,529	$ 	15,806	$ 	17,276	$ 	16,400	$ 	65,011	$ 	15,775	$ 	16,112	$ 	16,657	$ 	15,624	$ 	64,168	$ 	5% 	1%
Costs, Expenses and Other
Cost of sales 	3,419 	3,557 	3,855 	5,551 	16,382 	3,540 	3,745 	4,080 	3,828 	15,193 	45% 	8%
Selling, general and administrative 	2,552 	2,649 	2,633 	2,898 	10,733 	2,483 	2,739 	2,731 	2,864 	10,816 	1% 	-1%
Research and development 	3,621 	4,048 	4,234 	3,886 	15,789 	3,992 	3,500 	5,862 	4,585 	17,938 	-15% 	-12%
Restructuring costs 	69 	560 	47 	213 	889 	123 	80 	56 	51 	309 	* 	*
Other (income) expense, net 	(35) 	(7) 	(238) 	432 	151 	(33) 	42 	(162) 	126 	(24) 	* 	*
Income Before Taxes 	5,903 	4,999 	6,745 	3,420 	21,067 	5,670 	6,006 	4,090 	4,170 	19,936 	-18% 	6%
Income Tax Provision 	818 	571 	958 	458 	2,804 	903 	545 	929 	425 	2,803
Net Income 	5,085 	4,428 	5,787 	2,962 	18,263 	4,767 	5,461 	3,161 	3,745 	17,133 	-21% 	7%
Less: Net Income (Loss) Attributable to Noncontrolling
Interests
6 	1 	2 	(1) 	9 	5 	6 	4 	2 	16
Net Income Attributable to Merck & Co., Inc., Rahway, N.J.,
USA
5,079	$ 	4,427	$ 	5,785	$ 	2,963	$ 	18,254	$ 	4,762	$ 	5,455	$ 	3,157	$ 	3,743	$ 	17,117	$ 	-21% 	7%
Earnings per Common Share Assuming Dilution 	2.01	$ 	1.76	$ 	2.32	$ 	1.19	$ 	7.28	$ 	1.87	$ 	2.14	$ 	1.24	$ 	1.48	$ 	6.74	$ 	-20% 	8%
Average Shares Outstanding Assuming Dilution 	2,531 	2,513 	2,498 	2,488 	2,507 	2,544 	2,544 	2,541 	2,537 	2,541
Tax Rate 	13.9% 	11.4% 	14.2% 	13.4% 	13.3% 	15.9% 	9.1% 	22.7% 	10.2% 	14.1%
* 100% or greater
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
Full Year
2025
2Q 	3Q 	4Q 	Full Year	1Q 	1Q 	2Q 	3Q
2024
4Q 	4Q 	Full Year
% Change
MERCK & CO., INC., RAHWAY, N.J., USA
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1a
2

-- 3 of 10 --

Fourth Quarter
Cost of sales 	5,551	$ 	1,054 	1,173 	2,227 	3,324	$
Selling, general and administrative 	2,898 	48 	2 	50 	2,848
Research and development 	3,886 	5 	(111) 	(106) 	3,992
Restructuring costs 	213 	213 	213 	–
Other (income) expense, net 	432 	206 	206 	226
Income Before Taxes 	3,420 	(1,107) 	(1,277) 	(206) 	(2,590) 	6,010
Income Tax Provision (Benefit) 	458 	(187) (3) 	(234) (3) 	(44) (3) 	(465) 	923
Net Income 	2,962 	(920) 	(1,043) 	(162) 	(2,125) 	5,087
Net Income Attributable to Merck & Co., Inc., Rahway, N.J.,
USA 	2,963 	(920) 	(1,043) 	(162) 	(2,125) 	5,088
Earnings per Common Share Assuming Dilution 	1.19	$ 	(0.37) 	(0.42) 	(0.06) 	(0.85) 	2.04	$
Tax Rate 	13.4% 	15.4%
Full Year
Cost of sales 	16,382	$ 	2,871 	1,484 	4,355 	12,027	$
Selling, general and administrative 	10,733 	120 	3 	123 	10,610
Research and development 	15,789 	19 	175 	194 	15,595
Restructuring costs 	889 	889 	889 	–
Other (income) expense, net 	151 	(3) 	(306) 	(309) 	460
Income Before Taxes 	21,067 	(3,007) 	(2,551) 	306 	(5,252) 	26,319
Income Tax Provision (Benefit) 	2,804 	(525) (3) 	(473) (3) 	65 (3) 	(60) (4) 	(993) 	3,797
Net Income 	18,263 	(2,482) 	(2,078) 	241 	60 	(4,259) 	22,522
Net Income Attributable to Merck & Co., Inc., Rahway, N.J.,
USA 	18,254 	(2,482) 	(2,078) 	241 	60 	(4,259) 	22,513
Earnings per Common Share Assuming Dilution 	7.28	$ 	(0.99) 	(0.83) 	0.10 	0.02 	(1.70) 	8.98	$
Tax Rate 	13.3% 	14.4%
Only the line items that are affected by non-GAAP adjustments are shown.
(4) Amount represents a net tax benefit, including a net benefit related to favorable audit reserve adjustments.
GAAP
Acquisition- and
Divestiture-Related Costs	
(1)	
Restructuring Costs (2)	
(Income) Loss from
Investments in Equity
Securities
Certain Other Items 	Adjustment
Subtotal 	Non-GAAP
The Company is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management
believes that providing non-GAAP information enhances investors’ understanding of the Company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures
internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in
part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.
(1) Amounts included in cost of sales for the fourth quarter and full year reflect expenses for the amortization of intangible assets, as well as the recognition of fair value step-up of inventories related to the Verona Pharma
acquisition. Cost of sales for the full year also includes intangible asset impairment charges. For the full year, cost of sales reflects a benefit from a decrease in the estimated fair value measurement of liabilities for contingent
consideration. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development
expenses reflect the amortization of intangible assets.
(2) Amounts primarily include employee separation costs, accelerated depreciation and asset impairment charges associated with facilities to be closed or divested, as well as contractual termination costs and related adjustments,
associated with activities under the Company's formal restructuring programs.
(3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
MERCK & CO., INC., RAHWAY, N.J., USA
FOURTH QUARTER AND FULL YEAR 2025 GAAP TO NON-GAAP RECONCILIATION
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2a
3

-- 4 of 10 --

Fourth Quarter
Cost of sales 	3,828	$ 	701 	121 	822 	3,006	$
Selling, general and administrative 	2,864 	29 	16 	45 	2,819
Research and development 	4,585 	12 	(1) 	11 	4,574
Restructuring costs 	51 	51 	51 	–
Other (income) expense, net 	126 	(31) 	152 	121 	5
Income Before Taxes 	4,170 	(711) 	(187) 	(152) 	(1,050) 	5,220
Income Tax Provision (Benefit) 	425 	(111) (3) 	(17) (3) 	(33) (3) 	(260) (4) 	(421) 	846
Net Income 	3,745 	(600) 	(170) 	(119) 	260 	(629) 	4,374
Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 	3,743 	(600) 	(170) 	(119) 	260 	(629) 	4,372
Earnings per Common Share Assuming Dilution 	1.48	$ 	(0.23) 	(0.07) 	(0.04) 	0.10 	(0.24) 	1.72	$
Tax Rate 	10.2% 	16.2%
Full Year
Cost of sales 	15,193	$ 	2,409 	495 	2,904 	12,289	$
Selling, general and administrative 	10,816 	117 	83 	200 	10,616
Research and development 	17,938 	72 	1 	73 	17,865
Restructuring costs 	309 	309 	309 	–
Other (income) expense, net 	(24) 	(79) 	45 	(34) 	10
Income Before Taxes 	19,936 	(2,519) 	(888) 	(45) 	(3,452) 	23,388
Income Tax Provision (Benefit) 	2,803 	(461) (3) 	(135) (3) 	(10) (3) 	(519) (4) 	(1,125) 	3,928
Net Income 	17,133 	(2,058) 	(753) 	(35) 	519 	(2,327) 	19,460
Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 	17,117 	(2,058) 	(753) 	(35) 	519 	(2,327) 	19,444
Earnings per Common Share Assuming Dilution 	6.74	$ 	(0.81) 	(0.30) 	(0.01) 	0.21 	(0.91) 	7.65	$
Tax Rate 	14.1% 	16.8%
Only the line items that are affected by non-GAAP adjustments are shown.
The Company is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-
GAAP information enhances investors’ understanding of the Company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to
measure the performance of the Company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. The non-GAAP information
presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and
divestitures. Amounts included in research and development expenses primarily reflect the amortization of intangible assets. Additionally, research and development expenses for the full year includes Animal Health intangible asset impairment charges.
Amounts included in other (income) expense, net, primarily reflect royalty income and a decrease in the estimated fair value measurement of liabilities for contingent consideration related to the prior termination of the Sanofi-Pasteur MSD joint venture.
(2) Amounts primarily include employee separation costs, accelerated depreciation and asset impairment charges associated with facilities to be closed or divested related to activities under the Company's formal restructuring programs.
(3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
(4) Represents benefits recorded in the fourth quarter and full year due to reductions in reserves for unrecognized income tax benefits resulting from the expiration of the statute of limitations for assessments related to federal income tax return years. The
benefit recognized in the fourth quarter relates to the 2020 federal tax return year and the benefit recognized for the full year relates to both the 2020 and 2019 federal tax return years.
GAAP 	Acquisition and Divestiture-
Related Costs (1) 	Restructuring Costs (2)	
(Income) Loss from
Investments in Equity
Securities
MERCK & CO., INC., RAHWAY, N.J., USA
FOURTH QUARTER AND FULL YEAR 2024 GAAP TO NON-GAAP RECONCILIATION
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2b
Non-GAAP	Certain Other Items 	Adjustment Subtotal
4

-- 5 of 10 --

MERCK & CO., INC., RAHWAY, N.J., USA
FRANCHISE / KEY PRODUCT SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3
2025 	2024 	4Q 	Full Year
1Q 	2Q 	3Q 	4Q 	Full Year 	1Q 	2Q 	3Q 	4Q 	Full Year 	Nom % Ex-Exch % 	Nom % 	Ex-Exch %
TOTAL SALES (1) 	$15,529 $15,806 	$17,276 $16,400 $65,011 	$15,775 	$16,112 $16,657 $15,624 $64,168 	5 	4 	1 	2
PHARMACEUTICAL 	13,638 	14,050 	15,611 	14,843 	58,142 	14,006 	14,408 	14,943 	14,042 	57,400 	6 	4 	1 	1
Oncology
Keytruda 	7,205 	7,956 	8,142 	8,337 	31,641 	6,947 	7,270 	7,429 	7,836 	29,482 	6 	5 	7 	7
Keytruda Qlex 	5 	35 	40 	- 	- 	- 	-
Alliance Revenue – Lynparza (2) 	312 	370 	379 	389 	1,450 	292 	317 	337 	365 	1,311 	7 	4 	11 	10
Alliance Revenue – Lenvima (2) 	258 	265 	258 	272 	1,053 	255 	249 	251 	255 	1,010 	7 	6 	4 	4
Welireg 	137 	162 	196 	220 	716 	85 	126 	139 	160 	509 	37 	37 	41 	41
Alliance Revenue – Reblozyl (3) 	119 	107 	136 	164 	525 	71 	90 	100 	110 	371 	48 	48 	41 	41
Vaccines (4)
Gardasil/Gardasil 9 	1,327 	1,126 	1,749 	1,031 	5,233 	2,249 	2,478 	2,306 	1,550 	8,583 	-34 	-35 	-39 	-39
ProQuad/M-M-R II/Varivax 	539 	609 	684 	619 	2,451 	570 	617 	703 	594 	2,485 	4 	3 	-1 	-2
Vaxneuvance 	230 	229 	226 	140 	825 	219 	189 	239 	161 	808 	-13 	-16 	2 	1
Capvaxive 	107 	129 	244 	279 	759 	47 	50 	97 	* 	* 	* 	*
RotaTeq 	228 	121 	204 	119 	673 	216 	163 	193 	139 	711 	-14 	-15 	-5 	-5
Pneumovax 23 	41 	38 	45 	42 	166 	61 	59 	68 	74 	263 	-43 	-44 	-37 	-37
Hospital Acute Care
Bridion 	441 	461 	439 	499 	1,841 	440 	455 	420 	449 	1,764 	11 	11 	4 	4
Prevymis 	208 	228 	266 	275 	978 	174 	188 	208 	215 	785 	28 	26 	25 	23
Zerbaxa 	70 	74 	81 	87 	312 	56 	62 	64 	70 	252 	24 	23 	24 	24
Dificid 	83 	96 	43 	25 	247 	73 	92 	96 	79 	340 	-68 	-68 	-27 	-27
Cardiometabolic & Respiratory
Winrevair 	280 	336 	360 	467 	1,443 	70 	149 	200 	419 	133 	133 	* 	*
Alliance Revenue - Adempas/Verquvo (5) 	106 	123 	112 	129 	470 	98 	106 	102 	109 	415 	18 	18 	13 	13
Adempas (6) 	68 	80 	82 	83 	312 	70 	72 	72 	73 	287 	14 	9 	9 	6
Ohtuvayre 	178 	178 	- 	- 	- 	-
Virology
Lagevrio 	102 	83 	138 	57 	380 	350 	110 	383 	121 	964 	-53 	-53 	-61 	-61
Isentress/Isentress HD 	90 	86 	82 	67 	325 	111 	89 	102 	92 	394 	-27 	-28 	-18 	-18
Delstrigo 	67 	83 	77 	79 	306 	56 	60 	65 	69 	249 	15 	9 	23 	20
Pifeltro 	45 	41 	43 	42 	171 	42 	39 	42 	40 	163 	6 	4 	5 	4
Neuroscience
Belsomra 	50 	40 	47 	49 	186 	46 	53 	78 	45 	222 	8 	9 	-16 	-16
Immunology
Simponi 	184 	172 	189 	543 	-100 	-100
Remicade 	39 	35 	41 	114 	-100 	-100
Diabetes (7)
Januvia 	549 	372 	382 	302 	1,604 	419 	405 	278 	232 	1,334 	30 	30 	20 	21
Janumet 	247 	251 	243 	199 	940 	251 	224 	204 	255 	935 	-22 	-22 	1 	2
Other Pharmaceutical (8) 	729 	584 	948 	658 	2,917 	632 	618 	638 	699 	2,590 	-6 	-5 	13 	13
ANIMAL HEALTH 	1,588 	1,646 	1,615 	1,505 	6,354 	1,511 	1,482 	1,487 	1,397 	5,877 	8 	6 	8 	9
Livestock 	924 	961 	1,023 	987 	3,896 	850 	837 	886 	889 	3,462 	11 	9 	13 	14
Companion Animal 	664 	685 	592 	518 	2,458 	661 	645 	601 	508 	2,415 	2 	0 	2 	2
Other Revenues (9) 	303 	110 	50 	52 	515 	258 	222 	227 	185 	891 	-71 	-15 	-42 	-6
*200% or greater
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(7) Total Diabetes sales were $876 million, $704 million, $703 million and $579 million in the first, second, third and fourth quarter of 2025, respectively, and $745 million, $715 million, $592 million and $546
million in the first, second, third and fourth quarter of 2024, respectively.	
(8) Includes Pharmaceutical products not individually shown above. Also reflects total alliance revenue for Koselugo of $44 million, $43 million, $214 million and $135 million in the first, second, third and fourth
quarter of 2025, respectively, and $38 million, $37 million, $39 million and $56 million in the first, second, third and fourth quarter of 2024, respectively.
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to
the receipt of upfront and milestone payments for out-licensed products were $95 million, $5 million, $11 million and $27 million in the first, second, third and fourth quarter of 2025, respectively, and $61
million, $15 million, $15 million and $15 million in the first, second, third and fourth quarter of 2024, respectively.
(1) Only select products are shown.	
(2) Alliance Revenue represents the Company's share of profits, which are product sales net of cost of sales and commercialization costs.	
(3) Alliance Revenue represents royalties.	
(4) Total Vaccines sales were $2,607 million, $2,370 million, $3,370 million and $2,364 million in the first, second, third and fourth quarter of 2025, respectively, and $3,424 million, $3,656 million, $3,675 million
and $2,693 million in the first, second, third and fourth quarter of 2024, respectively.	
(5) Alliance Revenue represents the Company's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.	
(6) Net product sales in the Company's marketing territories.
5

-- 6 of 10 --

MERCK & CO., INC., RAHWAY, N.J., USA
FRANCHISE / KEY PRODUCT SALES
FOURTH QUARTER 2025
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3a
Global 	U.S. 	International
4Q 2025 	4Q 2024 	% Change 	4Q 2025 	4Q 2024 	% Change 	4Q 2025 	4Q 2024 	% Change
TOTAL SALES (1) 	$16,400 	$15,624 	5 	$9,139 	$8,188 	12 	$7,261 	$7,436 	-2
PHARMACEUTICAL 	14,843 	14,042 	6 	8,662 	7,728 	12 	6,181 	6,314 	-2
Oncology
Keytruda 	8,337 	7,836 	6 	4,892 	4,841 	1 	3,445 	2,996 	15
Keytruda Qlex 	35 	- 	33 	- 	2 	-
Alliance Revenue – Lynparza (2) 	389 	365 	7 	180 	177 	1 	209 	187 	12
Alliance Revenue – Lenvima (2) 	272 	255 	7 	191 	182 	5 	80 	73 	11
Welireg 	220 	160 	37 	181 	146 	24 	39 	14 	170
Alliance Revenue – Reblozyl (3) 	164 	110 	48 	133 	88 	51 	31 	22 	37
Vaccines (4)
Gardasil/Gardasil 9 	1,031 	1,550 	-34 	406 	380 	7 	625 	1,170 	-47
ProQuad/M-M-R II/Varivax 	619 	594 	4 	427 	419 	2 	192 	175 	9
Capvaxive 	279 	50 	* 	258 	49 	* 	21 	0 	*
Vaxneuvance 	140 	161 	-13 	50 	64 	-22 	90 	96 	-6
RotaTeq 	119 	139 	-14 	60 	84 	-28 	59 	55 	8
Pneumovax 23 	42 	74 	-43 	8 	19 	-61 	35 	55 	-37
Hospital Acute Care
Bridion 	499 	449 	11 	451 	382 	18 	49 	67 	-28
Prevymis 	275 	215 	28 	130 	106 	23 	146 	109 	33
Zerbaxa 	87 	70 	24 	50 	40 	25 	36 	30 	23
Dificid 	25 	79 	-68 	17 	72 	-76 	8 	7 	13
Cardiometabolic & Respiratory
Winrevair 	467 	200 	133 	432 	192 	125 	35 	9 	*
Ohtuvayre 	178 	- 	178 	-
Alliance Revenue - Adempas/Verquvo (5) 	129 	109 	18 	112 	105 	7 	17 	5 	*
Adempas (6) 	83 	73 	14 	83 	73 	14
Virology
Delstrigo 	79 	69 	15 	14 	14 	-1 	65 	55 	19
Isentress/Isentress HD 	67 	92 	-27 	37 	38 	-3 	30 	53 	-44
Lagevrio 	57 	121 	-53 	11 	32 	-65 	45 	88 	-49
Pifeltro 	42 	40 	6 	26 	26 	-3 	17 	13 	23
Neuroscience
Belsomra 	49 	45 	8 	22 	19 	18 	27 	26 	1
Diabetes (7)
Januvia 	302 	232 	30 	180 	41 	* 	122 	191 	-36
Janumet 	199 	255 	-22 	57 	91 	-37 	142 	164 	-14
Other Pharmaceutical (8) 	658 	699 	-6 	126 	121 	4 	531 	581 	-9
ANIMAL HEALTH 	1,505 	1,397 	8 	448 	444 	1 	1,056 	953 	11
Livestock 	987 	889 	11 	209 	203 	3 	777 	686 	13
Companion Animal 	518 	508 	2 	239 	241 	-1 	279 	267 	4
Other Revenues (9) 	52 	185 	-71 	29 	16 	81 	24 	169 	-86
*200% or greater
(6) Net product sales in the Company's marketing territories.
(7) Total Diabetes sales were $579 million and $546 million on a global basis in the fourth quarter of 2025 and 2024, respectively.
(8) Includes Pharmaceutical products not individually shown above. Also reflects total alliance revenue for Koselugo of $135 million and $56 million on a global
basis in the fourth quarter of 2025 and 2024, respectively.
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including
revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $27 million and $15
million in the fourth quarter of 2025 and 2024, respectively.
Sum of U.S. plus international may not equal global due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents the Company's share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties.
(4) Total Vaccines sales were $2,364 million and $2,693 million on a global basis in the fourth quarter of 2025 and 2024, respectively.
(5) Alliance Revenue represents the Company's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and
commercialization costs.
6

-- 7 of 10 --

MERCK & CO., INC., RAHWAY, N.J., USA
FRANCHISE / KEY PRODUCT SALES
FULL YEAR 2025
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3b
Global 	U.S. 	International
Full Year
2025 	Full Year 2024 % Change
Full Year
2025 	Full Year 2024 % Change
Full Year
2025
Full Year
2024 	% Change
TOTAL SALES (1) 	$65,011 	$64,168 	1 	$36,510 	$32,277 	13 	$28,501 	$31,891 	-11
PHARMACEUTICAL 	58,142 	57,400 	1 	34,409 	30,290 	14 	23,733 	27,110 	-12
Oncology
Keytruda 	31,641 	29,482 	7 	18,829 	17,872 	5 	12,812 	11,610 	10
Keytruda Qlex 	40 	- 	38 	- 	2 	-
Alliance Revenue – Lynparza (2) 	1,450 	1,311 	11 	683 	626 	9 	767 	685 	12
Alliance Revenue – Lenvima (2) 	1,053 	1,010 	4 	737 	705 	4 	316 	305 	4
Welireg 	716 	509 	41 	603 	466 	29 	113 	43 	161
Alliance Revenue – Reblozyl (3) 	525 	371 	41 	432 	303 	42 	93 	68 	37
Vaccines (4)
Gardasil/Gardasil 9 	5,233 	8,583 	-39 	2,641 	2,425 	9 	2,592 	6,158 	-58
ProQuad/M-M-R II/Varivax 	2,451 	2,485 	-1 	1,885 	1,919 	-2 	566 	566 	0
Vaxneuvance 	825 	808 	2 	459 	461 	0 	366 	347 	5
Capvaxive 	759 	97 	* 	730 	96 	* 	29 	1 	*
RotaTeq 	673 	711 	-5 	426 	472 	-10 	246 	239 	3
Pneumovax 23 	166 	263 	-37 	21 	56 	-63 	146 	207 	-30
Hospital Acute Care
Bridion 	1,841 	1,764 	4 	1,631 	1,401 	16 	209 	363 	-42
Prevymis 	978 	785 	25 	475 	371 	28 	503 	414 	21
Zerbaxa 	312 	252 	24 	186 	146 	28 	126 	106 	18
Dificid 	247 	340 	-27 	202 	303 	-33 	45 	37 	20
Cardiometabolic & Respiratory
Winrevair 	1,443 	419 	* 	1,358 	408 	* 	85 	11 	*
Alliance Revenue - Adempas/Verquvo (5) 	470 	415 	13 	421 	388 	8 	49 	27 	81
Adempas (6) 	312 	287 	9 	312 	287 	9
Ohtuvayre 	178 	- 	178 	-
Virology
Lagevrio 	380 	964 	-61 	101 	176 	-43 	278 	787 	-65
Isentress/Isentress HD 	325 	394 	-18 	181 	185 	-3 	144 	209 	-31
Delstrigo 	306 	249 	23 	56 	56 	1 	250 	193 	29
Pifeltro 	171 	163 	5 	111 	113 	-1 	59 	50 	18
Neuroscience
Belsomra 	186 	222 	-16 	82 	72 	13 	104 	150 	-31
Immunology
Simponi 	543 	-100 	543 	-100
Remicade 	114 	-100 	114 	-100
Diabetes (7)
Januvia 	1,604 	1,334 	20 	999 	469 	113 	605 	865 	-30
Janumet 	940 	935 	1 	268 	161 	66 	672 	774 	-13
Other Pharmaceutical (8) 	2,917 	2,590 	13 	676 	640 	6 	2,244 	1,951 	15
ANIMAL HEALTH 	6,354 	5,877 	8 	1,953 	1,861 	5 	4,401 	4,016 	10
Livestock 	3,896 	3,462 	13 	807 	732 	10 	3,089 	2,729 	13
Companion Animal 	2,458 	2,415 	2 	1,146 	1,129 	2 	1,312 	1,287 	2
Other Revenues (9) 	515 	891 	-42 	148 	126 	17 	367 	765 	-52
*200% or greater
(6) Net product sales in the Company's marketing territories.
(7) Total Diabetes sales were $2,862 million and $2,599 million on a global basis for December YTD 2025 and 2024, respectively.
(8) Includes Pharmaceutical products not individually shown above. Also reflects total alliance revenue for Koselugo of $436 million and $170 million on a global basis for December
YTD 2025 and 2024, respectively.
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities.
Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $138 million and $106 million on a global basis for December YTD 2025
and 2024, respectively.
Sum of U.S. plus international may not equal global due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents the Company's share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties.
(4) Total Vaccines sales were $10,711 million and $13,448 million on a global basis for December YTD 2025 and 2024, respectively.
(5) Alliance Revenue represents the Company's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
7

-- 8 of 10 --

MERCK & CO., INC., RAHWAY, N.J., USA
PHARMACEUTICAL GEOGRAPHIC SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3c
2025 	2024 	% Change
1Q 	2Q 	3Q 	4Q 	Full Year 	1Q 	2Q 	3Q 	4Q 	Full Year 	4Q 	Full Year
TOTAL PHARMACEUTICAL 	$13,638 	$14,050 	$15,611 $14,843 	$58,142 	$14,006 $14,408 	$14,943 	$14,042 	$57,400 	6 	1
United States 	7,927 	8,328 	9,493 	8,662 	34,409 	6,936 	7,399 	8,227 	7,728 	30,290 	12 	14
% Pharmaceutical Sales 	58.1% 	59.3% 	60.8% 	58.4% 	59.2% 	49.5% 	51.4% 	55.1% 	55.0% 	52.8%
Europe (1) 	2,384 	2,551 	2,675 	2,839 	10,449 	2,555 	2,572 	2,620 	2,498 	10,246 	14 	2
% Pharmaceutical Sales 	17.5% 	18.2% 	17.1% 	19.1% 	18.0% 	18.2% 	17.9% 	17.5% 	17.8% 	17.9%
Japan 	651 	604 	693 	684 	2,632 	802 	664 	919 	813 	3,199 	-16 	-18
% Pharmaceutical Sales 	4.8% 	4.3% 	4.4% 	4.6% 	4.5% 	5.7% 	4.6% 	6.2% 	5.8% 	5.6%
Latin America 	589 	654 	691 	644 	2,578 	601 	661 	730 	680 	2,672 	-5 	-4
% Pharmaceutical Sales 	4.3% 	4.7% 	4.4% 	4.3% 	4.4% 	4.3% 	4.6% 	4.9% 	4.8% 	4.7%
Asia Pacific (other than China and Japan) 	535 	609 	593 	586 	2,323 	580 	595 	669 	612 	2,457 	-4 	-5
% Pharmaceutical Sales 	3.9% 	4.3% 	3.8% 	4.0% 	4.0% 	4.1% 	4.1% 	4.5% 	4.4% 	4.3%
China (2) 	668 	407 	377 	364 	1,816 	1,744 	1,790 	996 	864 	5,394 	-58 	-66
% Pharmaceutical Sales 	4.9% 	2.9% 	2.4% 	2.5% 	3.1% 	12.5% 	12.4% 	6.7% 	6.2% 	9.4%
Eastern Europe/Middle East/Africa 	435 	451 	365 	348 	1,598 	395 	353 	400 	348 	1,495 	0 	7
% Pharmaceutical Sales 	3.2% 	3.2% 	2.3% 	2.3% 	2.7% 	2.8% 	2.4% 	2.7% 	2.5% 	2.6%
Canada 	125 	135 	134 	153 	547 	138 	143 	133 	144 	558 	6 	-2
% Pharmaceutical Sales 	0.9% 	1.0% 	0.9% 	1.0% 	0.9% 	1.0% 	1.0% 	0.9% 	1.0% 	1.0%
Other 	324 	311 	590 	563 	1,790 	255 	231 	249 	355 	1,089 	59 	64
% Pharmaceutical Sales 	2.4% 	2.1% 	3.9% 	3.8% 	3.2% 	1.9% 	1.6% 	1.5% 	2.5% 	1.7%
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom.
(2) Gardasil/Gardasil 9 sales in China were $193 million, $0, $0 and $0 in the first, second, third and fourth quarter of 2025, respectively, and $1,253 million, $1,312 million, $517 million and $446 million in the first, second, third, and
fourth quarter of 2024, respectively.
8

-- 9 of 10 --

OTHER (INCOME) EXPENSE, NET
4Q25 	4Q24
Full Year
2025
Full Year
2024
Interest income 	(69)	$ 	(146)	$ 	(343)	$ 	(415)	$
Interest expense 	412 	328 	1,357 	1,271
Exchange losses 	99 	49 	323 	227
Loss (income) from investments in equity securities, net (1) 196 	156 	(368) 	(14)
Net periodic defined benefit plan (credit) cost other than service cost 	(163) 	(157) 	(615) 	(633)
Other, net 	(43) 	(104) 	(203) 	(460)
Total 	432	$ 	126	$ 	151	$ 	(24)	$
(1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment
funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from
ownership interests in investment funds are accounted for on a one quarter lag.
MERCK & CO., INC., RAHWAY, N.J., USA
OTHER (INCOME) EXPENSE, NET - GAAP
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 4
9

-- 10 of 10 --